• 608-698-4470
  • contact@xylome.com

Advisory



Dale A. Monceaux – Fermentation Process

Dale A. Monceaux is a leading ethanol technologist with more than 30 years experience in process technology development and plant design, construction, commissioning, startup and operations in petrochemical and renewable fuels. In this time he has developed advanced enzymatic hydrolysis, fermentation, distillation and separation processes commercially applied in corn, wheat, barley based dry-mill fuel ethanol facilities as well as starch slurry, cassava, cane sugar and molasses plants with production capacities up to 100 million gallons per year. As the founder of AdvanceBio, LLC – a renewable energy and chemicals firm he has consulted on a broad range technologies related to conventional feedstock (starch and sugar based) as well as biomass (lignocellulosic) based biofuels and biochemical projects. Technology development and design activities include 2nd Generation Ethanol projects with notable developments in the areas of pretreated biomass liquefaction, large-scale fermentation system design and management, fermentation organism nutrient optimization and stillage processing. In his prior role as Sr. Vice President for Katzen International, Inc., Dale resolved numerous process engineering problems for grain ethanol production facilities.

Michele M Hooper, MD, MS – Medical Safety

Dr. Michele Hooper MD, is a graduate of the McGill University Medical School. Dr. Hooper’s distinguished career at Amgen and in Academic medicine specialized in Safety and Rheumatology, respectively. At Amgen, Dr. Hooper held positions of increasing responsibility up to the level of Executive Medical Director. Dr. Hooper managed product Safety in Inflammation, Oncology and Clinical Development. Dr. Hooper provided strategic direction for benefit risk assessment of Phase 2, 3 and 4 products including Regulatory Filing activities. She Co-chaired Global Regulatory and Safety Policy Expert Review Group responsible for drafting corporate responses to regulatory agencies, other legislative policies and conducted due diligence for mergers and acquisitions at Amgen. Dr. Hooper’s areas of expertise include Pharmacovigilance and Pharmacoepidemiology, clinical trial Development and Medical Affairs. Prior to Amgen, Dr. Hooper’s Academic career in Rheumatology championed new concepts of psoriasis as a systemic inflammatory disease and designed multipronged program including a partnership with Mayo Clinic to assess heart disease in psoriasis. At Case Western Reserve University School of Medicine, Dr. Hooper was a member of the University Hospital’s Institutional Review Board. Earlier she was an Assistant Professor of Medicine at the University of Rochester School of Medicine and Dentistry, Clinical Associate Professor of Orthopedics, Clinical Program and Clinical Trials Unit Director, Division of Allergy, Immunology and Rheumatology with experience in Private Rheumatology Practice, Rochester, NY. Dr. Hooper’s Board Certifications include Rheumatology at the University of Virginia, Charlottesville, VA, Allergy/Immunology at the University of Rochester, residency at Rochester General Hospital and intern at St. Michael’s Hospital, Toronto, Canada. She is a member of the American College of Rheumatology and Drug Information Association and author of 27 peer reviewed publications, 2 book chapters and numerous abstracts.